LT3001 Drug:low dose
Phase 2Small molecule
LT3001 Drug:low dose is one of 28 small molecule programs targeting Ischemic stroke. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
430 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Repatha
AmgenPreclinical
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Statins
SanofiPreclinical
LT3001 Drug:low dose
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 2
Urokinase
Mmedac GmbH
Preclinical
Drug Therapy
MMassachusetts General Hospital
Preclinical
Ginkgo Biloba Extract
NNational Center for Complementary and Integrative Health (NCCIH)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LT3001 Drug:low dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details